Investigative Report on Chinese Omalizumab Markets, 2016-2020 and 2021-2025: Developed by Novartis Europharm – The Only Approved Antibody Designed to Target and Block Immunoglobulin E (IgE)


DUBLIN, March 07, 2022–(BUSINESS WIRE)–The “Chinese Omalizumab Market Investigation Report 2021-2025” report has been added to from offer.

Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE).

The analyst predicts that with the increase in the number of indications, sales of Omalizumab in China will continue to grow from 2021 to 2025.

China is one of the countries with the highest asthma death rate in the world. In 2020, there were about 30 million asthma patients in China, 1.5 times more than the number of patients in 2017 (20 million). Therefore, it can be assumed that the number of indications for Omalizumab in China will continue to grow and sales will increase accordingly.

Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled ß2-adrenergic receptor agonists, particularly in patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future.

Additionally, Omalizumab has only been approved for one indication in China, and 4 indications have been approved worldwide. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase in the number of indications in the future.

At the end of 2017, the FDA approved the registration of Novartis Europharm’Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. As of the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese market for omalizumab.

According to the market research, sales of omalizumab increased year on year from 2018 to 2020. In early 2020, omalizumab was included in Chinese medical insurance as a treatment for respiratory diseases.

During the period of the COVID-19 outbreak, sales of Omalizumab increased. Therefore, its sales value reached CNY 41.61 million in China in 2020, with an annual growth rate of 281.5%. The sales value CAGR of Omalizumab in the Chinese market from 2018 to 2020 is 163.2%.

Topics Covered:

  • The Impact of COVID-19 on the Chinese Omalizumab Market

  • Omalizumab sales value in China 2016-2020

  • Competitive Landscape of Chinese Omalizumab Market

  • Omalizumab price in China

  • Omalizumab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese Omalizumab market

  • China omalizumab market outlook from 2021 to 2025

Main topics covered:

1 Relevant concept of Omalizumab

1.1 Indications for omalizumab

1.2 Development of Omalizumab in China

1.3 Government approval of Omalizumab in China

1.4 The impact of COVID-19 on Omalizumab sales in China

2 China Omalizumab Sales, 2018-2020

2.1 Omalizumab Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Omalizumab Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Omalizumab Sales by Dosage Form, 2018-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Omalizumab Key Manufacturers in China, 2018-2020

3.1 Omalizumab Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Novartis Europharma

3.2.1 Company profile

3.2.2 XOLAIR (Omalizumab by Novartis Europharm) Sales in China

4 omalizumab prices for different manufacturers in China, 2020-2021

4.1 Novartis Europharm (XOLAIR)

4.2 Analysis of other companies

5 China Omalizumab Drug Market Outlook, 2021-2025

5.1 Influencing Factors of China Omalizumab Market Development

5.1.1 The impact of COVID-19 on the Chinese omalizumab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

List of graphics

Chart Patent Information for Omalizumab Injection Registration in China

Omalizumab Injection sales value graph worldwide

Chart China Omalizumab Injection Sales Value, 2018-2020

Chart China Omalizumab Injection Sales Value by Region, 2018-2020

Chart China Omalizumab Injection Sales Volume, 2018-2020

Chart China Omalizumab Injection Sales Volume by Region, 2018-2020

Chart Market share by sales value of top manufacturers of Omalizumab in China, 2018-2020

Chart China XOLAIR Sales Value and Volume, 2018-2020

Chart XOLAIR Benchmark Price in China, 2020-2021

Chart China Omalizumab Sales Value Forecast, 2021-2025

Chart China Omalizumab Sales Volume Forecast, 2021-2025

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900


Comments are closed.